IRIS
LODI, Tiziana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.578
AS - Asia 6.158
EU - Europa 4.544
SA - Sud America 826
AF - Africa 274
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 5
Totale 19.395
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.391
SG - Singapore 2.329
CN - Cina 1.801
VN - Vietnam 947
IE - Irlanda 813
IT - Italia 777
SE - Svezia 681
BR - Brasile 647
FI - Finlandia 557
UA - Ucraina 490
HK - Hong Kong 467
DE - Germania 419
FR - Francia 220
ZA - Sudafrica 208
NL - Olanda 191
GB - Regno Unito 151
TR - Turchia 146
CA - Canada 130
BD - Bangladesh 124
RU - Federazione Russa 75
IN - India 64
AR - Argentina 51
IQ - Iraq 45
JP - Giappone 39
BE - Belgio 36
EC - Ecuador 32
MX - Messico 32
ES - Italia 29
CO - Colombia 28
KR - Corea 27
PL - Polonia 21
PH - Filippine 20
UZ - Uzbekistan 19
VE - Venezuela 18
ID - Indonesia 17
PK - Pakistan 17
CL - Cile 16
PY - Paraguay 13
EG - Egitto 12
CI - Costa d'Avorio 11
CZ - Repubblica Ceca 11
MA - Marocco 10
SA - Arabia Saudita 10
TH - Thailandia 10
TW - Taiwan 10
DO - Repubblica Dominicana 9
PE - Perù 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
AT - Austria 8
DZ - Algeria 7
EU - Europa 7
IR - Iran 7
LT - Lituania 7
PT - Portogallo 7
KE - Kenya 6
KZ - Kazakistan 6
RS - Serbia 6
TN - Tunisia 6
AL - Albania 5
AZ - Azerbaigian 5
JM - Giamaica 5
JO - Giordania 5
NO - Norvegia 5
NP - Nepal 5
BG - Bulgaria 4
CH - Svizzera 4
LB - Libano 4
OM - Oman 4
RO - Romania 4
AU - Australia 3
BA - Bosnia-Erzegovina 3
DK - Danimarca 3
KG - Kirghizistan 3
MK - Macedonia 3
NG - Nigeria 3
NI - Nicaragua 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
BY - Bielorussia 2
CG - Congo 2
CY - Cipro 2
ET - Etiopia 2
GE - Georgia 2
GY - Guiana 2
IL - Israele 2
KH - Cambogia 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
AW - Aruba 1
BO - Bolivia 1
CR - Costa Rica 1
DM - Dominica 1
EE - Estonia 1
Totale 19.377
Salva come PNG Salva come JPEG
Città #
Singapore 1.109
Ashburn 814
Dublin 802
Chandler 791
San Jose 674
Santa Clara 582
Jacksonville 541
Hong Kong 440
Beijing 415
Dallas 365
Ann Arbor 282
Dearborn 282
Ho Chi Minh City 279
Boardman 237
Hanoi 209
Nanjing 209
Parma 207
Johannesburg 192
Los Angeles 175
Princeton 155
Lauterbourg 137
San Mateo 132
New York 128
Izmir 123
Wilmington 119
Shanghai 110
Toronto 89
Jinan 75
Shenyang 71
São Paulo 65
Hefei 61
Nanchang 61
Helsinki 59
Des Moines 54
Moscow 53
Kunming 52
Munich 51
Woodbridge 50
Hebei 48
Buffalo 46
Haiphong 42
Da Nang 39
Guangzhou 38
Council Bluffs 37
Brussels 34
Tianjin 33
Falls Church 30
Jiaxing 30
Columbus 27
Tokyo 27
Changsha 26
Dosolo 26
Houston 26
Seattle 25
The Dalles 23
Brooklyn 22
Orem 21
Rio de Janeiro 21
Baghdad 20
Phoenix 20
Zhengzhou 20
Amsterdam 19
Atlanta 19
Frankfurt am Main 19
Rome 19
Redmond 18
Warsaw 18
Padova 17
Bremen 16
Can Tho 16
Haikou 16
London 16
Marseille 16
Milan 16
Tashkent 16
Catania 15
Hangzhou 15
Belo Horizonte 14
Biên Hòa 14
Bologna 14
Chennai 14
Denver 14
Fremont 14
Fuzhou 14
Hải Dương 13
Modena 13
San Francisco 13
Seoul 13
Taizhou 13
Chicago 12
Montreal 12
Nuremberg 12
Quito 12
Abidjan 11
Norwalk 11
Redwood City 11
Turku 11
Auburn Hills 10
Brasília 10
Guayaquil 10
Totale 11.487
Salva come PNG Salva come JPEG
Nome #
Mechanistic insights on the mode of action of an antiproliferative thiosemicarbazone-nickel complex revealed by an integrated chemogenomic profiling study 332
A yeast-based repurposing approach revealed modulation of dNTP pool as a therapeutic target to treat mitochondrial DNA depletion syndromes 217
Yeast, worm, patient’s fibroblasts and zebrafish as models for drug repositioning of molecules targeting POLG-related diseases 209
A chemical genomic approach to characterize the antiproliferative activity of metal based drugsdriven by phenotypic screening in yeast as a model organism 200
DNA polymerase [gamma] and disease: what we have learned from yeast 198
A chemical genomic approach to characterize the antiproliferative activity of metal-based drugs driven by phenotipic screening in yeast as a model organism 196
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 192
Biallelic Mutations of Methionyl-tRNA Synthetase Cause a Specific Type of Pulmonary Alveolar Proteinosis Prevalent on Réunion Island 192
Characterization of a promoter mutation in the CYP3 gene of S. cerevisiae which cancels regulation by Cyp1p (Hap1p) without affecting its binding site 189
Sabotage at the powerhouse? Unraveling the Molecular Target of 2-Isopropylbenzaldehyde Thiosemicarbazone, a Specific Inhibitor of Aflatoxin Biosynthesis and Sclerotia Development in Aspergillus flavus, Using Yeast as a Model System 187
Amino and carboxy-terminal extensions of yeast mitochondrial DNA polymerase assemble both the polymerization and exonuclease active sites 183
Screening of thiosemicarbazones as antimycotic drugs 179
A Klaac null mutant of Kluyveromyces lactis is complemented by a single copy of the Saccharomyces cerevisiae AAC1 gene 178
Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models 178
Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy 177
A single nucleotide polymorphism in the DNA polymerase gamma gene of Saccharomyces cerevisiae laboratory strains is responsible for increased mitochondrial DNA mutability 175
Defective mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome 173
A yeast-based repurposing approach for the treatment of mitochondrial DNA depletion syndromes led to the identification of molecules able to modulate the dNTP pool 171
Complete loss-of-function of the heart/muscle-specific adenine nucleotide translocator is associated with mitochondrial myopathy and cardiomyopathy 168
IMP2, a nuclear gene controlling the mitochondrial dependence of galactose, maltose and raffinose utilization in Saccharomyces cerevisiae. 166
In vitro evaluation of the activity of thiosemicarbazone derivatives against mycotoxigenic fungi affecting cereals 166
The Power of Yeast in Modelling Human Nuclear Mutations Associated with Mitochondrial Diseases 164
Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy 164
Combined use of Saccharomyces cerevisiae, Caenorhabditis elegans and patient fibroblasts leads to the identification of Clofilium tosylate as a potential therapeutic chemical against POLG-related diseases 164
S. cerevisiae carrying a MGM1/OPA1 chimeric gene: a model for the study of dominant optic atrophy and for drug discovery 163
Allelism of IMP1 and GAL2 genes of Saccharomyces cerevisiae 162
Yeast as a model of mitochondrial dysfunctions: neurodegenerative diseases and cancer. 161
Drug repositioning as a therapeutic strategy for neurodegenerations associated with OPA1 mutations 161
Behaviour of Saccharomyces cerevisiae wine strains during adaptation to unfavourable conditions of fermentation on synthetic medium: Cell lipid composition, membrane integrity, viability and fermentative activity 159
The identification of beneficial molecules for mitochondrial diseases: Saccharomyces cerevisiae as powerful model 159
A steric gate prevents mutagenic dATP incorporation opposite 8-oxo-deoxyguanosine in mitochondrial DNA polymerases 158
Carbon catabolite repression in Kluyveromyces lactis: isolation and characterization of the KlDLD gene encoding the mitochondrial enzyme D-lactate ferricytochrome c oxidoreductase. 157
Investigation of mupirocin susceptibility in bifidobacteria: physiological and genetic insights. 157
Antimycin- and hydroxamate-insensitive respiration in yeast 153
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 152
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 151
A yeast-based screening unravels potential therapeutic molecules for mitochondrial diseases associated with dominant ant1 mutations 151
Cloning and characterization of the lactate-specific inducible gene KlCYB2, encoding the cytochrome b2 of Kluyveromyces lactis 150
Construction and validation of a yeast model system for studying in vivo the susceptibility to stavudine of DNA polymerase gamma allelic variants 150
Dominance of yeast aac2R96H and aac2R252G mutations, equivalent to pathological mutations in ant1, is due to gain of function 149
Overexpression of DNA Polymerase Zeta Reduces the Mitochondrial Mutability Caused by Pathological Mutations in DNA Polymerase Gamma in Yeast 148
Genetic and chemical rescue of the Saccharomyces cerevisiae phenotype induced by mitochondrial DNA polymerase mutations associated with progressive externalophthalmoplegia in humans 147
A variable neurodegenerative phenotype with polymerase gamma mutation 146
Yeast expression of mammalian Onzin and fungal FCR1 suggests ancestral functions of PLAC8 proteins in mitochondrial metabolism and DNA repair 146
Efficient clofilium tosylate-mediated rescue of POLG-related disease phenotypes in zebrafish 145
The mitochondrial disulfide relay system protein GFER is mutated in autosomal-recessive myopathy with cataract and combined respiratory-chain deficiency. 144
Catabolite repression by galactose in overexpressed GAL4 strains of Saccharomyces cerevisiae 144
Chiral Aminoacid Containing Acyclic Ligands. I. Syntheses and Conformations 144
A mitochondrial role in pseudohyphal constitutive mutants obtained from a natural Saccharomyces cerevisiae strain 140
DEFECTIVE MITOCHONDRIAL rRNA METHYLTRANSFERASE (MRM2) CAUSES A MELAS-LIKE SYNDROME 140
Polymorphisms in DNA polymerase γ affect the mtDNA stability and the NRTI-induced mitochondrial toxicity in Saccharomyces cerevisiae 140
Identification of drugs for the treatment of POLG-related diseases by means of a high throughput drug repurposing approach performed in Saccharomyces cerevisiae 140
Characterization of KlGUT2, a gene of the glycerol-3-phosphate shuttle, in Kluyveromyces lactis 139
Expression of a lipocalin in Pichia pastoris: secretion, purification and binding activity of a recombinant Major Urinary Protein 138
Construction and validation of a yeast model system for studying in vivo the susceptibility to stavudine of Polg allelic variants 136
Carboxylic acids permeases in yeast: two genes in Kluyveromyces lactis.” 136
Mutations in AAC2, equivalent to human adPEO-associated ANT1 mutations, lead to defective oxidative phosphorylation in Saccharomyces cerevisiae and affect mitochondrial DNA stability 135
Construction of a yeast model system for studying in vivo susceptibility to stavudine of Polg allelic variants 135
Zebrafish polg2 knock-out recapitulates human POLG-disorders; implications for drug treatment 134
Saccharomyces cerevisiae as a system to discover beneficial molecules for mitochondrial diseases 134
Overexpression of DNA polymerase zeta and Rev1 reduces the mitochondrial mutability caused by pathological mutations in DNA polymerase gamma in yeast. 132
Secretion of human serum albumin from Kluyveromyces lactis over-expressing KlPDI1 and KlERO1 genes 131
Klaac null mutant in K. lactis is complemented by a single copy of S. cerevisiae “silent” gene AAC1 131
LYS2 gene and its mutation in Kluyveromyces lactis 129
Comparative Functional Genomics of glucose repression in laboratory and wine yeasts 129
Modification of nuclear gene expression by inhibition of mitochondrial translation during sporulation in MATa/Mata diploids of Saccharomyces cerevisiae. 128
Modeling of pathogenic variants of mitochondrial DNA polymerase: insight into the replication defects and implication for human disease 127
Defective mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome 126
Mutations in AAC2, equivalent to human adPEO-associated ANT1 mutations, lead to defective oxidative phosphorylation in Saccharomyces cerevisiae and affect mitochondrial DNA stability 124
Overexpression of DNA polymerase zeta reduces the mitochondrial mutability caused by pathological mutations in DNA polymerase gamma in yeast. 122
Saccharomyces cerevisiae, a model system to study the effect of mtDNA polymerase mutations associated with PEO in humans. 121
“Expression and structural characterization of a recombinant mouse major urinary protein” 120
“Espressione e secrezione di una Major Urinary Protein di topo nel lievito metilotrofo Pichia pastoris” 119
Structural modification of cuminaldehyde thiosemicarbazone increases inhibition specificity toward aflatoxin biosynthesis and sclerotia development in Aspergillus flavus 118
MIG1-dependent and MIG1-independent regulation of GAL gene expression in Saccharomyces cerevisiae: role of IMP2p 116
“Expression of a lipocalin in Pichia pastoris: secretion, purification and binding activity of a recombinant Major Urinary Protein” 116
The power of yeast in modeling human mutations leading to mitochondrial disease 116
Klaac null mutant in Kluyveromycs lactis is complemented by a single copy of Saccharomyces cerevisiae gene AAC1 116
Construction and characterization of centromeric, episomal and GFP-containing vectors for Saccharomyces cerevisiae prototrophic strains 115
Studio del sistema ADP/ATP carrier in Kluyveromyces lactis: effetti fenotipici della distruzione del gene KlAAC e della introduzione del gene ScAAC1 nel mutante derivato. 114
Mitmed: a multicenter consortium for the identification and characterization of nuclear genes responsisble for human mitochondrial disorders 114
Elementi regolativi implicati nel processo di repressione /derepressione da glucosio in Kluyveromyces lactis: differenze rispetto a Saccharomyces cerevisiae 113
Il lievito come modello per lo studio di patologie mitocondriali umane 113
Yeast model for drug discovery: Identification of molecules acting as potential therapeutics for POLG-related diseases 113
Effetti fenotipici e funzionali di mutazioni del gene ANT1 responsabili della patologia umana adPEO nel lievito Saccharomyces cerevisiae 112
FOG1 and FOG2 genes, required for the transcriptional activation of glucose-repressible genes of Kluyveromyces lactis are homologous to GAL83 and SNF1 of Saccharomyces cerevisiae 112
Klaac null mutant in K.lactis is complemented by a single copy of S.cerevisiae gene AAC1 111
Three target genes for the transcriptional activator Cat8p of Kluyveromyces lactis: acetyl coenzyme A synthetase genes KlACS1 and KlACS2 and lactate permease gene KlJEN1 111
L'aumento del dosaggio del gene ero1 favorisce la secrezione di proteine ricombinanti in Kluyveromyces lactis 110
“MAJOR URINARY PROTEINS: STUDIES ON THE BINDING OF FLUORESCENT MOLECULES AND ITS 13C AND 15N ENRICHED EXPRESSION IN PICHIA PASTORIS” 109
Oxygen is required to restore flor strain viability and lipid biosynthesis under fermentative conditions 109
Studio degli effetti fenotipici e funzionali di mutazioni del gene ANT1 responsabili della patologia umana adPEO nel lievito Saccharomyces cerevisae 109
Galactose transport in Kluyveromyces lactis: a genomic approach 109
Recurrent De Novo Dominant Mutations in SLC25A4 Cause Severe Early-Onset Mitochondrial Disease and Loss of Mitochondrial DNA Copy Number 109
Yeast as a model for drug discovery: Identification of a molecule acting as potential therapeutics for POLG-related diseases 108
Mutation D104G in ANT1 gene: complementation study in Saccharomyces cerevisiae as a model system 107
Isolation of DLD gene of Saccharomyces cerevisiae encoding the mitochondrial enzyme D-lactate ferricytochrome c oxidoreductase 107
Regulation of heat shock response in Saccharomyces cerevisiae. 107
Predicting the contribution of novel POLG mutations to human disease through analysis in yeast model 107
Rescue by Pol zeta overexpression of mitochondrial DNA instability due to mutations in Pol gamma in S. cerevisiae 106
Totale 14.468
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.940
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.940
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202144 0 0 0 0 0 0 0 0 0 0 0 44
2021/2022787 22 16 15 36 25 24 103 120 34 67 50 275
2022/20232.873 312 276 217 220 232 329 28 193 934 18 87 27
2023/20241.028 54 86 33 30 89 241 85 112 15 88 80 115
2024/20253.286 36 176 191 224 385 505 103 132 398 280 237 619
2025/20266.756 581 668 723 644 974 377 833 195 929 513 232 87
Totale 19.628